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echocardiographyAbstract Background: Left atrium (LA) dilatation has been associated with adverse cardiovascu-
lar outcomes in patients with sinus rhythm and atrial fibrillation (AF).
Aim of the study: We aimed to evaluate the accuracy of left atrial (LA) size to predict trans-
esophageal echocardiographic (TEE) markers of increased thromboembolic risk left atrial appen-
dage (LAA) thrombus, low LAA velocities and dense spontaneous echocardiographic contrast
(SEC), and also to assess the best method to evaluate LA size.
Patients and methods: Cross-sectional study included 64 patients with nonvalvular AF undergoing
transthoracic and transesophageal echocardiographic (TTE and TEE) evaluation. LA size was mea-
sured on TTE by several methods including the following: anteroposterior diameter (AP), LA area
in four and two apical chamber views and volumes by ellipsoid, single plane (1P) and biplane area-
length (2P) formulas. All these measures were indexed to the body surface area (BSA). Thromboem-
bolic markers including LAA thrombus, low LAA velocities, dense SEC and LA abnormality (LA
ABN) which means the presence of one or more of the previous three parameters were evaluated by
TEE.
Results: There was statistically significant increase in indexed and non-indexed LA parameters in
patients with LA ABN compared to patients without LA ABN. According to ROC curve, the study
found that all indexed LA parameters were predictive for LAA thrombus with the highest AUC was
indexed LA 1P area length volume (AUC 0.91, CI 95% 0.81–1.01, p< 0.000), for LAA low flow
velocity were indexed and non-indexed LA AP diameters with the highest AUC was indexed LAa; DM,
r; INR,
taneous
hy
.: +20
patients
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with nonvalvular atrial fibrillation: A cross-sAP diameter (AUC 0.89, CI 95% 0.80–0.98, p< 0.000), for LA dense SEC were indexed LA
ellipsoid volume (AUC 0.78, CI 95% 0.66–0.96, p= 0.002) and indexed LA 1P area length volume
(AUC 0.78, CI 95% 0.66–0.90, p= 0.002) and for LA ABN were all LA parameters with the high-
est AUC was indexed LA 1P area length volume (AUC 0.87, CI 95% 0.79–0.96, p< 0.000). On
multivariate logistic regression analysis of TEE parameters, the study found that the most predic-
tive LA measurement for LAA thrombus was indexed LA AP diameter with cutoff 3 cm/m2 (OR
7.5, 95% CI 1.24–45.2, p= 0.02), for LAA low flow velocity was LA AP diameter with cutoff
6 cm (OR 17.6, 95% CI 3.23–95.84, p= 0.001), for LA dense SEC was indexed LA ellipsoid volume
with cutoff 42 cm3/m2 (OR 6.5, 95% CI 1.32–32.07, p= 0.02), and for LA ABN was indexed LA
ellipsoid volume with cutoff 42 cm3/m2 (OR 10.45, 95% CI 2.18–51.9, p= 0.008).
Conclusion: LA enlargement is suitable to predict thromboembolic markers in patients with non-
valvular AF. The indexed and non-indexed LA AP diameter and indexed LA ellipsoid volume were
the most accurate parameters for predicting thromboembolic markers.
 2016 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Enlargement of left atrium (LA) has been established as a
prognostic marker for adverse CV outcomes such as atrial fib-
rillation,1,2 stroke,3 congestive heart failure,4 and cardiovascu-
lar death.5 Different methods exist for the assessment of LA
size. The American Society of Echocardiography recom-
mended LA volume and its indexed value assessed by 2-
dimensional echocardiography to measure LA size.6
The pathogenesis of LAA thrombus has not been fully
elucidated, but the prediction for its formation in the LAA
is likely to result from stagnation within the long, blind
ended trabeculated pouch.7 Diminished contractility of the
appendage understandably leads to reduction in blood flow
as well.8
LAA thrombus is associated with a large LAA area.9 The
prevalence of LA/LAA thrombi gradually increases with the
number of clinical risk factors.10 The LAA is the site most
commonly associated with thrombus formation, particularly
in patients with nonvalvular AF.5 Larger LA and LAA sizes
are associated with lower LAA flow velocity and risk of
ischemic stroke.11,8
Transesophageal echocardiography (TEE) is sensitive in the
assessment of parameters associated with thromboembolism
including thrombus in the LA appendage (LAA thrombus),12
dense spontaneous echocardiographic contrast (SEC), low
LA appendage flow velocities (low LAA velocities).13,14 The
presence of at least one of the three previous TEE changes
has been designated by left atrial abnormality (LA ABN)
and is associated with a risk of stroke of 7.8% a year.15
TEE is the most sensitive and specific technique to detect
LAA thrombus in patients with AF prior to cardioversion
and radiofrequency ablation procedures.16 However, several
studies demonstrated that LAA is free of thrombi in 86%
of AF patients who underwent a TEE prior to cardioversion.17
The cost implications of this practice are particularly impor-
tant because TEE is an increasingly utilized procedure,18 in
addition to the associated risk of complications such as oral
and esophageal trauma and the risks of conscious sedation.19
Therefore, there may be a role for risk stratification in patients
with AF to determine the need for a TEE to exclude the pres-
ence of LAA thrombus prior to cardioversion and radiofre-
quency ablation procedures.I Relation between left atrial measureme
ectional study, The Egypt Heart J (2012. Aim of the study
This study aims to evaluate the accuracy of LA size to predict
transesophageal echocardiographic (TEE) markers of
increased thromboembolic risk left atrial appendage (LAA)
thrombus, low LAA velocities and dense spontaneous echocar-
diographic contrast (SEC), and also to assess the best method
to evaluate LA size.
3. Patients and methods
3.1. Patients
This is a cross-sectional study included 65 patients with nonva-
lvular atrial fibrillation (AF) admitted to cardiology depart-
ment or referred to transthoracic and transesophageal
echocardiography (TTE and TEE) from outpatient cardiology
clinic in Zagazig University Hospitals from November 2014 to
April 2015. Exclusion criteria were patients with mitral steno-
sis, mitral regurgitation (moderate or severe), aortic stenosis
(moderate or severe), prosthetic mitral or aortic valves,
patients with unsuitable images for accurate assessment of
transthoracic echocardiography (TTE) measurements or trans-
esophageal echocardiography (TEE) markers of thromboem-
bolic risk and any contraindication to TEE.
3.2. Methods
3.2.1.
All patients in the study were subjected to the following:
complete medical history and physical examination including
calculated body surface area (BSA), body mass index
(BMI),20 CHADS2 and CHA2DS2-VASc scores.21,22 Electro-
cardiogram (ECG) and laboratory examination includes pro-
thrombin time, international normalized ratio (INR) and
glomerular filtration rate (GFR).
3.2.1. Transthoracic echocardiography
All patients underwent Doppler echocardiographic examina-
tion using a commercially available system (GE). Examinations
were performed by three trained echo cardiographers according
to American society of echocardiography. M-mode and two-nts and thromboembolic risk markers assessed by echocardiography in patients
6), http://dx.doi.org/10.1016/j.ehj.2016.05.004
Relation between left atrial measurements and thromboembolic risk markers 3dimensional transthoracic images were acquired using a M4S
probe (1.5–4.0 MHz), and were used to obtain the following
LA measurements: LA anteroposterior diameter (LA AP), left
atrium (LA) area, and LA volumes by the ellipsoid, single plane
(1P) area length and biplane (2P) area length methods. These
measurements were obtained at end-ventricular systole, from
the frame immediately preceding mitral valve opening. LA
anteroposterior (LA AP) diameter (D1) was measured by M-
mode from the parasternal long axis view. LA area was mea-
sured using planimetry in (TTE) apical four chamber (A1)
and two chamber views (A2) as shown in Fig. 1.
LA ellipsoid volume (LAEV) was calculated using AP (D1),
medial–lateral (D2) and superior–inferior (D3) LA diameters
so LA EV= 4/3p*(D1/2) * (D2/2) * (D3/2). LA single plane
area length volume (LA 1P) was obtained using A1 represent-
ing the area and D3 the superior–inferior LA diameter mea-
sured from apical four chamber (4C) view so LA
1P = 8/3p*A12/D3. Left atrium biplane area-length volume
(LA 2P) was obtained using A2 representing the LA area in
two chamber view, and L the shortest superior inferior diam-
eter measured in apical four chamber (D3) and two chamber
(D4) views using this formula LA 2P = 8/3p*[(A1) * (A2)/
L].6 All these measurements were indexed to body surface area.
3.2.2. Transesophageal echocardiography
TEE images were acquired with a 6 T phased array multiplane
TEE probe (2.9–7.0 MHz). The LA and LA appendage (LAA)
were imaged in different tomographic planes to detect the pres-
ence of LAA thrombus, SEC and LAA flow velocities. LA
thrombus was diagnosed by the presence of an echo dense
mass in the left atrium or the LAA.23 Spontaneous echocardio-
graphic contrast was diagnosed by the presence of characteris-
tic dynamic smoke-like swirling echoes in the LA or LAA,24
and was classified according to the classification (1 to 4+).
Dense SEC was defined as grade 3+ or 4+.25 LAA flow veloc-
ities were assessed with a pulsed Doppler sample placed 1 cm
from LAA into the body of the LA. Maximum emptying
and filling velocities were estimated from an average of five
well-defined emptying and filling waves. Patients with maxi-
mum emptying and filling velocity 620 cm/s were classified
as having low flow velocities.26
4. Study endpoints
The study endpoints were the TEE surrogate markers of
thromboembolism as LAA thrombus, LAA low flow velocitiesFigure 1 Echocardiographic parameters used to calculate the left atria
LA AP diameter; D2 – medial–lateral diameter; D3 – superior-inferior
Lang et al.6
Please cite this article in press as: Radwan HI Relation between left atrial measureme
with nonvalvular atrial fibrillation: A cross-sectional study, The Egypt Heart J (201and dense SEC. The composite endpoint of LA abnormality
was defined by the presence of at least one of the previous
markers.
5. Ethics
Informed parental consent was obtained to be eligible for
enrollment into the study. The study was done according to
the rules of the Local Ethics Committee of Faculty of Medi-
cine, Zagazig University, Egypt.
6. Statistical analysis
All analyses were made using the ‘‘SPSS 17 for Windows” soft-
ware package. Continuous variables were expressed as mean
± standard deviation; categorical variables were expressed as
percentages. Independent T-test was used to compare means.
Chi-square test was used to compare percentages. ROC curve
was plotted to get cutoff value. We used multiple linear regres-
sion analysis of TTE parameters to predict thromboembolic
risk. A p value of <0.05 means significant and p< 0.001
means highly significant.
7. Results
Basic characteristics of the study population are summarized
in Table 1 which shows that the mean age of the studied group
was 67.03 ± 5.9 years. There was higher prevalence of males
(62.5%). The average CHA2DS2-VASc scores was 3.66
± 1.2. The INR ranged from 1 to 2.7 with mean 1.69
± 0.57. We found that 43.7% of the studied group had
AF 6 one week (paroxysmal AF), 26.6% had AF for more
than 1 week to one year (persistent AF), 29.7% had AF for
more than one year (long standing persistent AF), 46.9% of
patients were on antiplatelet, 40.6% were on oral anticoagu-
lants and 31.1% were on enoxaparine.
Echocardiographic findings of the study population are
shown in Table 2: TEE examinations identified 8 patients
(12.5%) had LAA thrombus, 10 patients (15.6%) had LAA
low flow velocities, 14 patients (21.9%) had dense SEC, and
26 patients (40.6%) had LA ABN.
Comparison of baseline characteristics of the study popula-
tion according to the presence of left atrium abnormalities (LA
ABN) is summarized in Table 3: patients with LA ABN had
statistically significantly higher body surface area (1.93l volumes. A1 – LA area in 4C view; A2 – LA area in 2C view D1 –
diameter in 4C view; D4 – superior-inferior diameter in 2C view.
nts and thromboembolic risk markers assessed by echocardiography in patients
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Table 1 Basic characteristics of the study population.
Demographic data N (64)
Age:(years) mean ± SD
Sex: no (%) 67.03 ± 5.9
Female 24 (37.5%)
Male 40 (62.5%)
Body mass index (kg/m2): mean ± SD 29.83 ± 4.41
Body surface area (m2): mean ± SD 1.88 ± 0.18
Clinical data: no (%)
Smoking 26 (40.6%)
Hypertension 54 (84.3%)
Diabetes 18 (28.1%)
Previous stroke/TIA 10 (15.6%)
Congestive heart failure 34 (53.1%)
Vascular disease 34 (53.1%)
Pacemaker or ICD 8 (12.5%)
CHA2DS2-VASc (mean ± SD) 3.66 ± 1.2
Laboratory data (mean ± SD)
Hemoglobin (g/dl) 13.05 ± 1.46
Platelet (103/lL) 232.56 ± 51.85
INR 1.69 ± 0.57
GFR (ml/min/1.73 m2) 66.77 ± 17.51
AF duration
648 h 15 (23.4%)
>48 h–1 week 13 (20.3%)
>1 week–1 year 17 (26.6%)
>1 year 19 (29.7%)
Antithrombotic treatment
Oral anticoagulation 26 (40.6%)
Antiplatelet agents 30 (46.9%)
Enoxaparine 20 (31.1%)
GFR: glomerular filtration rate, ICD: implantable cardioverter
defibrillator, INR: international normalized ratio. TIA: transient
ischemic attack. Vascular disease is defined as having at least one of
the following: myocardial infarctions, peripheral artery disease, and
complex aortic plaque.
Table 2 Echocardiographic findings of the study population.
Echocardiographic finding (n= 64)
TTE (mean ± SD)
LA AP diameter (cm) 5.51 ± 1.1
LA area (cm2) 26.3 ± 6.47
LA ellipsoid volume (cm3) 78.53 ± 16.15
LA 1P area-length volume (cm3) 131.26 ± 27.04
LA 2P area-length volume (cm3) 111.64 ± 25.89
LV ejection fraction (%) 47.63 ± 11.66
TEE (no & %)
LAA thrombus 8 (12.5%)
LAA low flow velocities 10 (15.6%)
Dense SEC 14 (21.9%)
LA ABN 26 (40.6%)
Table 3 Comparison of baseline characteristics of the study
population according to the presence of left abnormality.
Demographic data Without LA
ABN (n= 38)
With LA
ABN (n= 26)
P
Age (years) mean
± SD
66.05 ± 6.2 68.46 ± 5.21 0.11
Body mass index (kg/
m2)
29.26 ± 4.76 30.67 ± 3.77 0.21
Body surface area (m2) 1.81 ± 0.19 1.93 ± 0.16 0.008
Sex:
Female 14 (36.8%) 10 (38.5%) 0.9
Clinical data: (n & % )
Smoking 18 (47.4%) 8 (30.8%) 0.18
Hypertension 34 (89.5%) 20 (76.9%) 0.17
Diabetes 6 (23.1%) 12 (31.6%) 0.46
Previous stroke/TIA 2 (7.7%) 8 (21.1%) 0.15
Congestive heart
failure
20 (52.6%) 14 (53.8%) 0.92
Vascular diseases 12 (46.2%) 22 (57.9%) 0.36
Pacemaker or ICD 4 (10.5%) 4 (15.4%) 0.56
CHADS2 1.77 ± 0.82 2.16 ± 1.1 0.003
CHA2DS2-VASc 3.46 ± 0.95 3.79 ± 1.34 0.002
Laboratory data: mean ± SD
Hemoglobin (g/d) 12.91 ± 1.54 13.25 ± 1.33 0.36
Platelet (103/lL) 241.79 ± 49.06 219.08 ± 53.8 0.09
INR 1.83 ± 0.62 1.49 ± 0.42 0.02
GFR (ml/min/1.73 m2) 64.37 ± 19.32 69.75 ± 14.29 0.26
AF duration: (n & % )
648 h 12 (31.6%) 3 (11.5%) 1
>48 h–1 week 11 (28.9%) 2 (7.7%) 0.11
>1 week–1 year 9 (23.7%) 8 (30.8%) 0.01
>1 year 6 (15.8%) 13 (50.0%) 0.004
Antithrombotic treatment:
Oral anticoagulation 20 (52.6%) 6 (23.1%) 0.02
Antiplatelet agent 12 (31.6%) 18 (69.2%) 0.003
Enoxaparine 16 (42.1%) 4 (15.4%) 0.02
4 H.I. Radwan± 0.16 vs 1.81 ± 0.19, p= 0.008), CHADS2 score (2.16
± 1.1 vs 1.77 ± 0.82 p= 0.003), CHADS–VASC score
(3.79 ± 1.34 vs 3.46 ± 0.95, p= 0.002) and significantly lower
INR (1.49 ± 0.42 vs 1.83 ± 0.62, p= 0.02) than patients
without LA ABN respectively. Also Patients with LA ABNPlease cite this article in press as: Radwan HI Relation between left atrial measureme
with nonvalvular atrial fibrillation: A cross-sectional study, The Egypt Heart J (201had longer AF duration more than one week, significantly
lower use of oral anticoagulants than patients without LA
ABN (23.1 vs 52.6%, p= 0.02).
There were statistically significant increases in all indexed
and non-indexed LA measurements and decrease in LV EF
in patients with LA ABN compared to patients without LA
ABN (Table 4).
ROC curve revealed LAA thrombus showing that are all
indexed and most non-indexed LA parameters that were sig-
nificant predictors of thromboembolic risk; however, the high-
est AUC was indexed LA 1P area length volume (AUC 0.91,
CI 95% 0.81–1.01, p= 0.000) followed by indexed LA area
(AUC 0.90, CI 95% 0.82–0.98, p= 0.000) (Table 5 and
Fig. 2).
ROC curve of LAA low flow velocity revealed that indexed
LA AP diameter (AUC 0.89, CI 95% 0.80–0.98, p= 0.000)
followed by non-indexed LA AP diameter (AUC 0.88, CI
95% 0.79–0.97, p= 0.000) was the highest predictor of throm-
boembolic risk (Table 6 and Fig. 3).
ROC curve of LA dense SEC revealed that all parameters
except anteroposterior diameter were significant predictors of
thromboembolic risk. However, the highest AUC was indexed
LA ellipsoid volume (AUC 0.78, CI 95% 0.66–0.96,nts and thromboembolic risk markers assessed by echocardiography in patients
6), http://dx.doi.org/10.1016/j.ehj.2016.05.004
Table 4 Comparison of echocardiographic findings according to the presence of left atrium abnormalities.
Characteristics (mean ± SD) Without ABN (n= 38) With ABN (n= 26) T P
LA AP diameter (cm) 5.12 ± 0.83 6.07 ± 1.21 3.73 0.000
LA area (cm2) 23.51 ± 6.34 30.38 ± 4.09 4.88 0.000
LA ellipsoid volume (cm3) 73.31 ± 16.97 86.16 ± 11.37 3.38 0.001
LA 1P area-length volume (cm3) 119.98 ± 28.21 147.75 ± 13.71 4.65 0.000
LA 2P area-length volume (cm3) 108.05 ± 27.04 128.62 ± 18.6 3.37 0.001
LV ejection fraction (%) 52.77 ± 10.43 44.11 ± 11.26 3.11 0.003
Indexed LA AP (cm/m2) 2.65 ± 0.35 3.39 ± 0.78 5.16 0.000
Indexed LA area (cm2/m2) 12.16 ± 3 17.01 ± 3.29 6.1 0.000
Indexed LA ellipsoid volume (cm3/m2) 37.92 ± 7.77 47.85 ± 6.76 5.29 0.001
Indexed LA 1p volume (cm3/m2) 62.25 ± 14.12 82.29 ± 10.90 6.09 0.000
Indexed LA 2p volume (cm3/m2) 56.01 ± 13.5 71.52 ± 12.26 4.68 0.001
P value <0.001 indicates highly significant difference.
Table 5 Validity of LA measurements in predicting LAA
thrombus as a marker for thromboembolic risk.
AUC 95% CI P
LA AP 0.75 0.62–0.87 0.02
Indexed LAAP 0.88 0.75–0.97 0.001
LA area 0.77 0.64–0.91 0.01
Indexed LA area 0.90 0.82–0.98 0.000
LA ellipsoid volume 0.63 0.46–0.79 0.26
Indexed LA ellipsoid volume 0.81 0.66–0.96 0.004
LA 1P volume 0.73 0.58–0.87 0.04
Indexed LA 1P volume 0.91 0.81–1.01 0.000
LA 2P volume 0.76 0.61–0.92 0.02
Indexed LA 2P volume 0.88 0.72–1.03 0.001
Relation between left atrial measurements and thromboembolic risk markers 5p= 0.002) and indexed LA 1P area length volume (AUC 0.78,
CI 95% 0.66–0.90, p= 0.002) (Table 7 and Fig. 4).
ROC curve of LA ABN showed that all LA parameters
were statistically significant in predicting LA ABN. However
the highest AUC was indexed LA 1P area length volumeFigure 2a ROC curve
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LA area (AUC 0.86, CI 95% 0.78–0.95, p= 0.000) (Table 8
and Fig. 5).
Multivariate logistic regression analysis found that the
most predictive LA measurement for LAA thrombus was
indexed LA AP with cutoff 3 cm/m2 (OR 7.5, 95% CI 1.24–
45.2, p= 0.02), for LAA low flow velocity was LA AP with
cutoff 6 cm (OR 17.6, 95% CI 3.23–95.84, p= 0.001), for
LA dense SEC was indexed LA ellipsoid volume with cutoff
42 cm3/m2 (OR 6.5, 95% CI 1.32–32.07, p= 0.02), and for
LA ABN was indexed LA ellipsoid volume with cutoff
42 cm3/m2 (OR 10.45, 95% CI 2.18–51.9, p= .008) followed
by indexed LA AP with cutoff 3 cm/m2 (OR 8.2, 95% CI
1.44–44.7, p= 0.01) and LA 1P area length volume with cut-
off 125 cm3 (OR 6, 95% CI 1.03–34, p= 0.04) (Table 9).8. Discussion
This study was conducted to evaluate the accuracy of LA size
to predict TEE markers of increased thromboembolic risk inof LAA thrombus.
nts and thromboembolic risk markers assessed by echocardiography in patients
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Figure 2b Detailed ROC curves of LAA thrombus.
Table 6 Validity of LA measurements in predicting LAA low
flow velocity.
AUC 95% CI P
LA AP 0.88 0.79–0.97 0.000
Indexed LAAP 0.89 0.80–0.98 0.000
LA area 0.65 0.50–0.80 0.14
Indexed LA area 0.66 0.49–0.83 0.11
LA ellipsoid volume 0.59 0.41–0.77 0.38
Indexed LA ellipsoid volume 0.62 0.42–0.81 0.25
LA 1P volume 0.71 0.54–0.87 0.04
Indexed LA 1P Volume 0.60 0.43–0.77 0.32
LA 2P volume 0.74 0.59–0.88 0.02
Indexed LA 2P Volume 0.65 0.50–0.81 0.13
Figure 3 Detailed ROC curve
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physiology procedure.
We found that the proportion of patients with LA ABN
was 40.6% of the study population (Table 2) which is higher
than reported by other previous studies. They found that the
proportion of patients with LA ABN was 26.3%, 15.6%,
8.8%, and 29.6%, of their study population respec-
tively.14,27–29 This high percentage of patients with LA ABN
can be at least partially explained by underutilization of oral
anticoagulants that were found in our study.
Provideˆncia et al.14 evaluated and compared the accuracy
of CHADS2 and CHA2DS2-VASc in the prediction of TEE
markers of thromboembolic risk and test the additive value
of transthoracic echocardiogram (TTE)-derived parameterss of LAA low flow velocity.
nts and thromboembolic risk markers assessed by echocardiography in patients
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Table 7 Validity of LA measurements in predicting dense
SEC as a marker for thromboembolic risk.
AUC 95% CI P
LA AP 0.59 0.41–0.77 0.31
Indexed LAAP 0.59 0.42–0.77 0.28
LA area 0.76 0.64–0.89 0.003
Indexed LA area 0.75 0.62–0.88 0.005
LA ellipsoid volume 0.76 0.65–0.90 0.003
Indexed LA ellipsoid volume 0.78 0.66–0.96 0.002
LA 1P volume 0.73 0.58–0.87 0.009
Indexed LA 1P volume 0.78 0.65–0.90 0.002
LA 2P volume 0.66 0.50–0.81 0.07
Indexed LA 2P volume 0.65 0.50–0.79 0.09
Figure 4a ROC curve
Figure 4b Detailed ROC c
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ble refinement for prediction of the TEE endpoints.
Ayirala et al.27 and Doukky et al.28 tested the hypothesis
that higher LA volume and/or lower left ventricular ejection
fraction (LVEF) and the ratio of LVEF to LA volume index
(LAVI) might prove valuable as markers of increased risk
for LA appendage thrombus formation in patients with nonva-
lvular AF.
Faustino et al.29 aimed to evaluate the accuracy of LA size
to identify TEE markers of thromboembolic risk in patients
with AF.
We found that use of anti-coagulants was significantly
lower among patients with LA ABN compared to patients
without LA ABN (23.1 vs 52.6%), p= 0.002 (Table 3). Theseof LA dense SEC.
urves of LA dense SEC.
nts and thromboembolic risk markers assessed by echocardiography in patients
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Table 8 Validity of LA measurements in predicting LA ABN
as a marker for thromboembolic risk.
AUC 95% CI P
LA AP 0.76 0.64–0.89 0.000
Indexed LAAP 0.80 0.68–0.91 0.000
LA area 0.82 0.72–0.93 0.000
Indexed LA area 0.86 0.78–0.95 0.000
LA ellipsoid volume 0.76 0.64–0.87 0.001
Indexed LA ellipsoid volume 0.83 0.72–0.93 0.000
LA 1P volume 0.81 0.71–0.92 0.000
Indexed LA 1P volume 0.87 0.79–0.96 0.000
LA 2P volume 0.77 0.65–0.88 0.000
Indexed LA 2P volume 0.78 0.67–0.89 0.000
Figure 5a ROC cu
Figure 5b Detailed ROC
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with nonvalvular atrial fibrillation: A cross-sectional study, The Egypt Heart J (201results are different from those reported by previous stud-
ies.14,27–29 They all found that use of anticoagulants was signif-
icantly higher among patients with LA ABN compared to
patients without LA ABN (42.4 vs 37.5%), (56.5 vs. 21%),
(83.3 vs. 44%) and (50 vs 36.6%) respectively. This may be
explained by less strict application of guidelines regarding
use of oral anticoagulants in our patients.
Our study found that patients with LA ABN had high
CHADS2 and CHA2DS2-VASc scores, and this can be
explained by high prevalence of thromboembolic risk factors
including older age, diabetes, previous stroke or TIA, vascular
diseases and heart failure. (Table 3) These results were concor-
dant with those reported by previous studies.14,28–30 Also Ayi-
rala et al.27 found that high CHADS(2) score was significant
predictors of LA appendage thrombus formation.rve of LA ABN.
curves of LA ABN.
nts and thromboembolic risk markers assessed by echocardiography in patients
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Table 9 Multivariate logistic regression analysis of transesophageal parameters of predicting thromboembolic risk.
OR 95%CI P
LA ABN Indexed LA ellipsoid volumeP 42 cm3/m2 10.45 2.18–51.9 0.008
Indexed LA APP 3 cm/m2 8.2 1.44–44.7 0.01
LA 1p area length volumeP 125 cm3 6 1.03–34 0.04
LAA thrombus Indexed LA APP 3 cm/m2 7.5 1.24–45.2 0.02
LA dense SEC Indexed LA ellipsoid volumeP 42 cm3/m2 6.5 1.32–32.07 0.02
LAA low flow velocity LA APP 6 cm 17.6 3.23–95.84 0.001
Relation between left atrial measurements and thromboembolic risk markers 9Our data showed significant increase in percentage of
patients with AF duration more than 1 week (persistent AF)
in patients with LA ABN compared to patients without LA
ABN (30.8 vs 23.7%), p< 0.01. However the study found
no significant difference between both groups regarding the
prevalence of paroxysmal AF (duration < 1 week). These
results were in agreement with Fatkin et al.25 and Faustino
et al.29, who found that patients with paroxysmal AF had no
LA ABN, while patients with longer AF duration (persistent
AF) had LA ABN.
We found that dilated LA size irrespective of the used
method, and lower LV EF were more prevalent in patients
with left atrial abnormalities (LA ABN). These results confirm
the results of previous studies.12,27–29
Zabalgoitia and colleagues12 found statistically significant
increase in LA measurements in patients with LA ABN com-
pared to patients without LA ABN.
Ayirala et al.27 and Doukky et al.28 found that the ratio of
LVEF to LA volume index 61.5 produced 100% sensitivity
for the presence of LA appendage thrombus. They used two dif-
ferent methods to calculate LA volume either three linear
dimensions (ellipsoid volume) or the area-length method. Both
of these methods are endorsed by the American Society of
Echocardiography guidelines.6 They concluded that the excel-
lent diagnostic performance of the prediction rule of this ratio
not affected by themethodwas used to calculate the LA volume.
Faustino et al.29 reported that LA dilation is associated
with an increase in the prevalence of LA ABN (TEE markers
of increased thromboembolic risk) in patients with AF, inde-
pendently from recognized clinical risk factors. A stronger
association was found for measurements indexed to body sur-
face area.
These results can be explained by decreased LVEF and ele-
vated LV filling pressure lead to LA dilatation and LAA
thrombus formation,31 chronic elevation in LA pressure leads
to LA volume and pressure overload and deterioration of
LAA contractility, leading to blood stasis and thrombus for-
mation,32 and also LA enlargement usually associated with
permanent AF, which is known independent predictor of
LAA thrombus formation.33
Our results suggest that a larger LA size was associated
with LA ABN. Also, most non-indexed and all indexed mea-
surements showed high accuracy in the prediction of all throm-
boembolic risk markers assessed by TEE without significant
differences between different parameters.
We found the highest AUC for the prediction of study end-
points was achieved with indexed LA 1P volume for LAA
thrombus (AUC 0.91, p< 0.000), dense SEC (AUC 0.87,
p< 0.000) and LA ABN (AUC 0.87, p< 0.000). Regarding
LAA low flow velocities, the highest AUC was obtained with
indexed LA AP (AUC 0.89, p< 0.000).Please cite this article in press as: Radwan HI Relation between left atrial measureme
with nonvalvular atrial fibrillation: A cross-sectional study, The Egypt Heart J (201Faustino et al.29 found that indexed measurements of LA
area 4C, LA 1P and 2P area-length volumes had moderate
to high discriminatory power in the prediction of LAA throm-
bus, LAA low flow velocities, dense SEC and LA ABN, with-
out significant differences between them. Indexed LA area 4C
was an independent predictor of all TEE endpoints. For LAA
thrombus, indexed 2P area-length volume was a predictor of
TEE surrogate markers of stroke.
Russo et al.34 evaluated single-plane and biplane methods
for the assessment of LA volume against three-dimensional
echocardiography in 527 participants of a community-based
Cohort. They found strong correlations between single- and
biplane LA volume measurements (r= 0.95, p< 0.01), and
single- (r= 0.93, p< 0.01) and biplane (r= 0.93, p< 0.01)
area-length with three-dimensional volumes.
On multivariate analysis, the present study found that the
most predictive LA parameter for LAA thrombus was indexed
LA AP with cutoff 3 cm/m2, for LA dense SEC was indexed
LA ellipsoid volume with cutoff 42 cm3/m2, for LAA low flow
velocity was LA AP with cutoff 6 cm and for LA ABN was LA
1P area length volume with cutoff 125 cm3 (Table 9).
Faustino et al.29 found that the most predictive LA param-
eter for LAA thrombus was indexed LA 2P volume, for LA
dense SEC, LAA low flow velocity and LA ABN were indexed
LA area, and also they found that no significant differences
between indexed LA area 4C, LA 2P and 1P area length vol-
ume for the discrimination of TEE markers of thromboem-
bolic risk.
9. Limitation
For single-center study with small sample size, we suggest that
multicenter approaches may be necessary to attain larger sam-
ple sizes. At the time of TEE, 40.6% of the patients were under
oral anticoagulation, which may have an impact on the preva-
lence of thromboembolic risk markers; we thought this is not
problem as some of patients on oral anticoagulants had sub
therapeutic INR, and also it is known that thrombi may arise
even under therapeutic INR. Finally as our study hypothesis is
based on surrogate TEE markers endpoints so it needs to be
clinically validated in an outcome study looking at systemic
thromboembolism, including stroke, as a main endpoint to
confirm the accuracy and advantages of TTE-derived LA
parameters in prediction of thromboembolic risk.
10. Conclusion
LA enlargement is suitable to predict TEE derived throm-
boembolic markers (LAA thrombus, LAA low flow velocities,
dense SEC and LA ABN) in patients with non-valvular AF.nts and thromboembolic risk markers assessed by echocardiography in patients
6), http://dx.doi.org/10.1016/j.ehj.2016.05.004
10 H.I. RadwanThe indexed LA ellipsoid volume, LA 1P area length volume,
and indexed and non-indexed LA AP diameter were the most
accurate methods for predicting thromboembolic surrogate
markers in these patients.
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